0
0.5
1
1.5
2+
Mortality
74%
Improvement
Relative Risk
ICU admission
49%
Hospitalization
37%
primary
Bamlanivimab/e.. Ganesh et al. LATE TREATMENT
Is late treatment with bamlanivimab/etesevimab beneficial for COVID-19?
Retrospective 3,621 patients in the USA
Lower hospitalization with bamlanivimab/etesevimab (p=0.014)
c19early.org
Ganesh et al., J. Clinical Investigation, Oct 2021
Favors bamlanivimab/e..
Favors control